Nexdiag | Revolutionising allergies diagnostics with the next generation of ultra-sensitive highly multiplexed diagnostic tests based on micro-pearls

Summary
The WHO predicts that half of the European population will suffer from allergies. Allergies are a growing burden for our society, our healthcare system and companies that have to take staff off work due to disabling symptoms.
Thanks to fluorescent µpearls and the discovery of Quantum Plates, Nexdot is developing a highly multiplexed diagnostic test that will allow to assay IgE on 500 allergens (and up to 1000) at once using only one drop of blood. This innovation will revolutionize the way allergies are treated by reducing drastically the time to diagnostic and its associated cost (x10-20 reduction).

Our technology could also be extended to serology tests, for detection of patient’s antibodies against infectious agents or cancer markers. It can be extended for global health for the easy and cost-effective detection of antigens as infectious or toxic agents in human, animals or environment for global health, or food for industry.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/190186747
Start date: 01-05-2023
End date: 31-10-2025
Total budget - Public funding: 3 628 125,00 Euro - 2 500 000,00 Euro
Cordis data

Original description

The WHO predicts that half of the European population will suffer from allergies. Allergies are a growing burden for our society, our healthcare system and companies that have to take staff off work due to disabling symptoms.
Thanks to fluorescent µpearls and the discovery of Quantum Plates, Nexdot is developing a highly multiplexed diagnostic test that will allow to assay IgE on 500 allergens (and up to 1000) at once using only one drop of blood. This innovation will revolutionize the way allergies are treated by reducing drastically the time to diagnostic and its associated cost (x10-20 reduction).

Our technology could also be extended to serology tests, for detection of patient’s antibodies against infectious agents or cancer markers. It can be extended for global health for the easy and cost-effective detection of antigens as infectious or toxic agents in human, animals or environment for global health, or food for industry.

Status

SIGNED

Call topic

HORIZON-EIC-2022-ACCELERATOROPEN-01

Update Date

31-07-2023
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon Europe
HORIZON.3 Innovative Europe
HORIZON.3.1 The European Innovation Council (EIC)
HORIZON.3.1.0 Cross-cutting call topics
HORIZON-EIC-2022-ACCELERATOR-01
HORIZON-EIC-2022-ACCELERATOROPEN-01 EIC Accelerator Open